U.S. Life Sciences Stock News

If you are wondering whether Allegion at around $164 a share is still a smart buy or if the easy gains are behind it, this breakdown will help you decide whether the current price makes sense. The stock is up 2.4% over the last week and 28.1% year to date, even after a modest 1.7% dip over the past month. This suggests that the market still sees solid long term potential in the story. Recent headlines have focused on Allegion expanding its presence in electronic and IoT enabled security...

Workday (WDAY) is back in the spotlight after a fresh upgrade to a Buy, with investors reassessing the stock as management lifts 2026 revenue guidance and leans into a sizable buyback. See our latest analysis for Workday. The upgrade lands after a choppy stretch, with the share price down around 11% year to date and a 1 year total shareholder return of roughly minus 18%. However, Workday’s solid three year total shareholder return of about 28% suggests longer term momentum is still intact as...

Recently, Centene was highlighted by Hotchkis & Wiley's Mid-Cap Value Fund for its leadership in managed Medicaid, while a Politico report indicated the White House intends to seek a two-year extension of Obamacare subsidies, supporting insurers focused on Affordable Care Act marketplaces. This combination of supportive policy signals and endorsement from a major institutional investor underscores how crucial government-backed programs are to Centene’s business model and future revenue...

On 9 December 2025, CorMedix director Steven W. Lefkowitz sold 40,000 shares of common stock for about US$475,200, leaving him with 80,498 shares, shortly after the company reported Q3 2025 earnings and revenue that significantly exceeded market forecasts. The combination of robust quarterly results and insider selling draws attention to how CorMedix’s recent operational momentum aligns with leadership’s portfolio decisions. With CorMedix’s Q3 earnings beating expectations, we’ll examine how...

Earlier this week, Archer-Daniels-Midland cut its full-year adjusted earnings guidance to US$3.25–US$3.50 per share, citing trade uncertainty with China and unclear biofuel policies despite beating quarterly earnings expectations. This guidance reset highlights how sensitive ADM’s profit outlook is to external policy and trade conditions across its global agricultural and biofuels operations. We’ll now examine how ADM’s reduced earnings guidance, driven by trade and biofuel policy...

Keurig Dr Pepper (KDP) has been quietly grinding higher, with the stock up about 10% over the past month and 8% in the past 3 months, even as its year to date return remains negative. See our latest analysis for Keurig Dr Pepper. That recent 30 day share price momentum of just over 10% is starting to chip away at a tougher year to date patch, even though the one year total shareholder return is still slightly negative. This suggests sentiment may be cautiously turning as investors reassess...

Wondering if Visa is still a buy at these levels, or if most of the upside has already been priced in? You are not alone. This is exactly where a closer look at valuation can give you an edge. Over the past week Visa has climbed 5.7%, is up 2.0% over the last month, and has gained 9.9% year to date, adding to a 10.8% return over the last year and roughly 70% over both three and five years. These moves have come as markets continue to reward dominant payment networks for their resilience and...

Eaton (ETN) has quietly become one of the market’s more interesting industrials, with the stock slipping about 5% over the past month even as its long term growth story remains intact. See our latest analysis for Eaton. At around $350.36, Eaton’s recent 30 day share price pullback of roughly 4.8% comes after a strong multi year run. The three year total shareholder return is still above 135%, suggesting momentum is cooling rather than broken. If Eaton’s move has you rethinking where the next...

Perdoceo Education (PRDO) has quietly pulled back almost 9% over the past month even as its longer term track record and steady revenue and earnings growth paint a very different picture for patient investors. See our latest analysis for Perdoceo Education. The recent slide looks more like a breather than a breakdown, with a 30 day share price return of negative 8.9% coming after a solid year to date share price gain and a standout three year total shareholder return above 120%. This suggests...

Amtech Systems (ASYS) has just posted its FY 2025 fourth quarter numbers, with revenue of about $19.8 million and EPS of roughly $0.07 setting the tone for the latest print. Over the past six quarters, the company has seen quarterly revenue move from about $24.1 million in Q4 2024 to a peak of $26.7 million in Q3 2024 before landing at $19.8 million in Q4 2025. Over the same period, EPS has swung from a loss of roughly $0.04 in Q4 2024 to a deep trough of about negative $2.23 in Q2 2025 and...

In recent days, Stoke Therapeutics and Biogen reported encouraging long-term Phase 1/2a and extension data for zorevunersen in Dravet syndrome, while Eisai and Biogen shared new clinical and real-world insights on LEQEMBI and its subcutaneous formulation for early Alzheimer’s disease, alongside additional regulatory milestones and broader market access moves. Yet, HSBC’s downgrade of Biogen on concerns over declining CD20 collaboration royalties and growth risks highlights how questions...

RedCloud Holdings (NasdaqCM:RCT) just posted its H1 2025 scorecard, with trailing twelve month revenue of about $48.4 million and a basic EPS of roughly -$1.76. This sets a clear backdrop of rapid top line expansion paired with ongoing losses. The company has seen revenue move from $13.6 million in H2 2023 to $16.1 million in H1 2024 and then $30.4 million in H2 2024. Over those same halves, EPS shifted from about -$4.20 to -$0.51 and then a much steeper -$17.85. That combination of fast...

John Wiley & Sons, Inc. recently reported fiscal Q2 2026 results showing slightly lower sales of US$421.75 million but higher net income of US$44.89 million, and completed a US$177.54 million buyback program while authorizing up to US$250 million in new repurchases. The company also lifted its quarterly dividend for the 32nd straight year and increased its Fiscal 2026 buyback allocation to US$100 million, underscoring management’s confidence in long-term demand for its content and AI-related...

Vail Resorts (MTN) opened fiscal Q1 2026 with revenue of about $271 million, a basic EPS loss of roughly $5.20, and net income excluding extra items of around negative $187 million, setting a cautious tone for the new season. The company has seen quarterly revenue move from about $260 million in Q1 2025 to roughly $271 million in Q1 2026, while basic EPS shifted from a loss of about $4.62 to a loss of roughly $5.20 over the same period, giving investors a mixed read on top line stability...

Bel Fuse (BELF.A) has quietly put up a strong run lately, with the stock gaining about 22% over the past month and more than 31% in the past 3 months. See our latest analysis for Bel Fuse. Zooming out, the recent rally fits into a much bigger move, with a strong year to date share price return helping push Bel Fuse to around $155.40 as investors warm to its growth trajectory and reassess risk. If Bel Fuse’s momentum has you rethinking your tech exposure, it might be a good moment to scan...

If you have been wondering whether SkyWest at around $107 a share is still good value after its big comeback, you are not alone. This article is designed to walk you through that question step by step. The stock has climbed 5.2% over the last week, 10.6% over the past month, and 495.2% over three years, which naturally raises the question of how much upside, or downside, might be left from here. Recently, investors have been focused on SkyWest’s progress in rebuilding regional capacity and...

Manchester United (NYSE:MANU) opened Q1 2026 with revenue of about £140.3 million and a basic EPS of roughly -£0.04, alongside net income of around -£6.6 million, keeping the club in loss-making territory even as it reports another busy quarter of activity. The club has seen quarterly revenue move between roughly £143.1 million and £198.7 million over the past year while EPS has swung from £0.01 to as low as about -£0.16, which sets up a narrative where a growing top line and negative EPS...

Wondering if Bloom Energy is still worth buying after its massive run up, or if the easy money has already been made? Let us break down what the recent action really implies for its underlying value. Despite a sharp pullback over the last week and month, with returns of -7.7% over 7 days and -14.2% over 30 days, the stock is still up an eye catching 366.4% year to date and 339.3% over the past year, with multi year gains above 300%. These swings have come as investor attention has shifted...

Payoneer recently announced a partnership with Oscilar, integrating its AI- and machine-learning-based fraud and risk intelligence platform across Payoneer’s core global payment systems to improve predictive monitoring and automation. This upgrade in fraud prevention aims to tighten risk controls while keeping customer interactions smooth, which could strengthen Payoneer’s competitive position in cross-border payments for small and medium-sized businesses. Next, we’ll examine how Payoneer’s...

Amentum Holdings (AMTM) just added another long term growth lever, landing a prime spot on the Defense Threat Reduction Agency's $3.5 billion CTRIC IV program alongside a fresh $120 million DISA computing services win. See our latest analysis for Amentum Holdings. Those twin defense wins seem to be feeding into the story, with the latest share price at $30.13 and a punchy 1 month share price return of 31.23% capping a 39.10% year to date share price gain. This suggests momentum is building as...

In recent days, Goldman Sachs has issued a series of fixed-income securities, including new callable senior notes across multiple maturities and a zero-coupon senior unsecured MTN, while also hosting its GS Asia Tech Tour conference and advancing acquisition plans for defined-outcome ETF provider Innovator Capital Management. Together with the launch of its firm-wide OneGS 3.0 AI program, these moves highlight Goldman’s push to deepen fee-based, technology-enabled businesses and diversify...

AMETEK (AME) just earned another year on BofA’s closely watched US 1 List, and its short interest ticked down. Together these moves underscore a market that is gradually leaning more optimistic on the stock. See our latest analysis for AMETEK. At a latest share price of $203.84, AMETEK’s steady year to date share price return and strong multi year total shareholder returns suggest momentum is quietly building as investors price in consistent growth and lower perceived risk. If AMETEK’s steady...

Sezzle (SEZL) just earned a spot in the S&P SmallCap 600, a move that is drawing fresh attention because index funds tracking it will now have to buy the stock, which could potentially lift trading volumes. See our latest analysis for Sezzle. The index news lands on top of an already strong run, with Sezzle’s share price at $73.85 and a year to date share price return of 62.43 percent, despite a weaker 90 day share price return of negative 17.27 percent. This suggests momentum is being tested...

Savara Inc. recently announced that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled GM-CSF therapy delivered via the eFlow Nebulizer System for the rare lung disease autoimmune pulmonary alveolar proteinosis. This prospective patent, alongside multiple expedited and orphan designations in the U.S., EU and U.K., could materially extend MOLBREEVI’s protection and enhance the company’s respiratory disease franchise if...